⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XFOR News
X4 Pharmaceuticals, Inc. Common Stock
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
XFOR
Norgine gibt die Marktzulassung der Europäischen Kommission für XOLREMDI® (Mavorixafor) bekannt, die erste zugelassene Behandlung für Patienten mit WHIM-Syndrom in der Europäischen Union USA - Deutsch USA - English USA - English USA - Français
prnewswire.com
XFOR
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
globenewswire.com
XFOR
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
XFOR
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
XFOR
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
globenewswire.com
XFOR
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
XFOR
Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome USA - English USA - Français USA - español USA - Deutsch USA - English
prnewswire.com
XFOR
Norgine celebra la opinión positiva del CHMP que recomienda la aprobación de mavorixafor USA - español USA - English USA - English USA - Deutsch USA - Français
prnewswire.com
XFOR
Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome USA - English USA - Français USA - español USA - Deutsch USA - English
prnewswire.com
XFOR